Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials

AIDS

Volumn 26, Issue 18, 2012, Pages 2295-2306

  Mexas, Angela M ^a   Graf, Erin H ^a   Pace, Matthew J ^a   Yu, Jianqing J ^a   Papasavvas, Emmanouil ^b   Azzoni, Livio ^b   Busch, Michael P ^c   Di Mascio, Michele ^d   Foulkes, Andrea S ^e   Migueles, Stephen A ^d   Montaner, Luis J ^b   O'Doherty, Una ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

integrated HIV DNA; ongoing replication; Pegylated IFN

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ATAZANAVIR; BIOLOGICAL MARKER; CD4 ANTIGEN; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; VIREMIA; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DISEASE RESERVOIRS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; VIRAL LOAD; VIREMIA; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84870250032     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a5c2f     Document Type: Article

References (68)

1. Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, et al. Engineering HIV-resistant human CD4R T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011;7:e1002020.
2. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
3. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4R T cell model without inducing global T cell activation. J Virol 2011;85:6060-6064.
4. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010;329:174-180.
5. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res 2010;85:286-294.
6. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011;25:885-897.
7. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009;323:1304-1307.
8. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517. (Pubitemid 29220209)
9. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295. (Pubitemid 27495741)
10. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-188. (Pubitemid 27209433)
11. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, et al. Resting CD4R T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004;78:6122-6133. (Pubitemid 38715910)
12. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008;122:22-28. (Pubitemid 351899083)
13. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193-13197. (Pubitemid 27518498)
14. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4R T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005;304:3-15.
15. Agosto LM, Liszewski MK, Mexas A, Graf E, Pace M, Yu JJ, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology 2011;409:46-53.
16. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIVR patients on and off HAART. PLoS Pathog 2011;7:e1001300.
17. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427. (Pubitemid 21917358)
18. Zhou Y, Zhang H, Siliciano JD, Siliciano RF. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4R T cells. J Virol 2005;79:2199-2210. (Pubitemid 40204577)
19. Zack JA, Haislip AM, Krogstad P, Chen ISY. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-1725.
20. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002;76:8518-8531. (Pubitemid 34864046)
21. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010;84:12971-12981.
22. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010;84:7018-7028.
23. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008;197:411-419. (Pubitemid 351263423)
24. Dickover RE, Donovan RM, Goldstein E, Cohen SH, Bolton V, Huth RG, et al. Decreases in unintegrated HIV DNA are associated with antiretroviral therapy in AIDS patients. J Acquir Immune Defic Syndr 1992;5:31-36.
25. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15:893-900.
26. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004;78:1160-1168. (Pubitemid 38095826)
27. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296. (Pubitemid 44837777)
28. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004;1:e64.
29. Davey RT, Bhat N, Yoder C, Chun T-W, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999;96:15109-15114. (Pubitemid 30019773)
30. Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 2009;47:254-260.
31. Yu JJ, Wu TL, Liszewski MK, Dai J, Swiggard WJ, Baytop C, et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 2008;379:78-86.
32. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive, quantitative, assay for human immunodeficiency virus type 1 integration. J Virol 2002;76:942-910.
33. Butler SL, Hansen MST, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631-634. (Pubitemid 32448333)
34. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4R T cell response. J Infect Dis 2011;203:960-968.
35. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003;41:4531-4536. (Pubitemid 37259753)
36. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011;204:135-138.
37. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010;202:1553-1561.
38. Azzoni L, Foulkes A, Papasavvas E, Mexas A, Lynn K, Mounzer K, et al. Pegylated intergeron-a2A mono-therapy results in suppression of HIV-1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. (in press).
39. Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoeven J, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004;35:33-37. (Pubitemid 38044779)
40. Pomerantz RJ, Otero M, Nunnari G, Malin A, Coates C, Dascenzo C, et al. Residual HIV-1 Disease Eradication (RHIDE) Trial: an HIV-1 eradication approach in humans using a novel and stimulatory intensification therapy. Poster 405-T. Seattle, WA; 2002.
41. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIVpositive adults on suppressive antiretroviral therapy. AIDS 2010;24:2451-2460.
42. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, Wong JK. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003;77:11212-11219. (Pubitemid 37204311)
43. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009;106:9403-9408.
44. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005;115:3250-3255. (Pubitemid 41567589)
45. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50:912-919.
46. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010;7:e1000321.
47. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4 (R) T cells in HIV elite controllers. Clin Infect Dis 2010;51:233-238.
48. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009;7:798-812.
49. Lafeuillade A, Stevenson M. The search for a cure for persistent HIV reservoirs. AIDS Rev 2011;13:63-66.
50. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008;105:3879-3884. (Pubitemid 351723493)
51. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005;79:5203-5210. (Pubitemid 40464268)
52. Sharkey ME, Teo I, Greenough TC, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 intermediates in patients on highly active antiretroviral therapy. Nat Med 2000;6:76-81 (Pubitemid 30048530)
53. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002;76:3739-3747. (Pubitemid 34250538)
54. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type-1 replication. J Virol 2002;76:4138-4144. (Pubitemid 34250581)
55. Murray JM, McBride K, Boesecke C, Bailey M, Amin J, Suzuki K, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 2012;26:543-550.
56. Zhu W, Jiao Y, Lei R, Hua W, Wang R, Ji Y, et al. Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. PLoS One 2010;6:e21081.
57. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011;7:e1001303.
58. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999;354:1782-1785.
59. Nakajima N, Lu R, Engelman A. Human immunodeficiency virus type 1 replication in the absence of integrase-mediated DNA recombination: definition of permissive and nonpermissive T-cell lines. J Virol 2001;75:7944-7955. (Pubitemid 32743666)
60. Sakai H, Kawamura M, Sakuragi J, Sakuragi S, Shibata R, Ishimoto A, et al. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 1993;67:1169-1174. (Pubitemid 23067618)
61. Pace M, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, et al. Directly infected resting CD4+T cells can produce HIV gag without spreading infection in a model of HIV latency. PLoS Pathog 2012;8:e1002818.
62. Hosmalin A, Lebon P. Type I interferon production in HIVinfected patients. J Leukoc Biol 2006;80:984-993. (Pubitemid 44646304)
63. Portales P, Reynes J, Rouzier-Panis R, Baillat V, Clot J, Corbeau P. Perforin expression in T cells and virological response to PEGinterferon alpha2b in HIV-1 infection. AIDS 2003;17:505-511. (Pubitemid 36293103)
64. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006;312:879-882. (Pubitemid 43727313)
65. Herbeuval JP, Shearer GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007;123:121-128. (Pubitemid 46590066)
66. Pitha PM. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antivir Res 1994;24:205-219. (Pubitemid 24228875)
67. Goujon C, Malim MH. Characterization of the alpha interferoninduced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 2010;84:9254-9266.
68. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, et al. Alpha interferon potently enhances the antihuman immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006;80:7645-7657. (Pubitemid 44092585)